Keywords
How to Cite
Abstract
The present review analyzes the use of L-ornithine-L-aspartate within pathogenic therapy for the patients having COVID‑19 and concomitant hepatic diseases, development of acute changes of the liver values, impairment of the liver’s detoxing function and the presence of the hidden or apparent liver encephalopathy.
References
World Health Organization. Coronavirus disease (COVID‑19) pandemic, 2020.https://www.who.int/publications/m/item/weekly-epidemiological-update-1-december‑2020
Li Y., Xiao S. Hepatic involvement in COVID‑19 patients: pathology, pathogenesis and clinical implications [Review] // J. Med. Virol. — 2020. — 92. — P. 1491-1494.
Sun J., Aghemo A., Forner A., Valenti L. COVID‑19, and liver disease // Liver Int. — 2020. — 40. — P. 1278-1281.
Walls A. C., et al. Structure, function, and antigenicity of the SARS-CoV‑2 spike glycoprotein // Cell. — 2020. — 181. — P. 281-292.
Singh H., Choudhari R., Nema V., Khan A. A. ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID‑19 disease // Microb. Pathog. — 2020. — 150. — P. 104621.
Gu, Y. et al. Interaction network of SARS-CoV‑2 with host receptome through spike protein. Preprint at 10.1101/2020.09.09.287508 (2020).
Hamming I., Timens W., Bulthuis M. L., Lely A. T., Navis G., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis // J. Pathol. — 2004. — 203. — P. 631-637.
Gao Q. Y., Chen Y. X., Fang J. Y. 2019 Novel coronavirus infection and gastrointestinal tract // J. Dig. Dis. — 2020. — 21. — P. 125-126.
Chen J., Chen J., Fu H., Li Y., Wang L., Luo S. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF‑2alpha/PPARalpha pathway // Am. J. Physiol. Endocrinol. Metab. — 2019. — 317. — E710-E22.
Bangash M. N., Patel J., Parekh D. COVID‑19, and the liver: little cause for concern // Lancet Gastroenterol. Hepatol. — 2020. — 5. — P. 529-530.
Wang Y., Liu S., Liu H., et al. SARS-CoV‑2 infection of the liver directly contributes to hepatic impairment in patients with COVID‑19 // J. Hepatol. — 2020. — 73. — P. 807-816.